Pyrrolopyrazine kinase inhibitors

A compound of Formula I

• wherein:
• R is R1, R2, R3, or R4;
• R1 is lower alkyl, lower alkoxy, phenyl, benzyl, heteroaryl, cycloalkyl, heterocycloalkyl, or cycloalkyl alkylene, optionally substituted with one or more R1a;
• R1a is R1b or R1c;
• each R1b is independently halogen, oxo, hydroxy, or —CN;
• each R1c is independently —C(═O)O(R1f), —C(═O)(R1e), —C(═O)CH2(R1e), —S(R1f), —S(O)2(R1f), —N(R1f)S(O)2(R1f), —S(═O)(R1f), lower alkyl, lower alkoxy, amino, amido, lower haloalkyl, phenyl, heteroaryl, cycloalkyl, heterocycloalkyl, cycloalkyloxy, or heterocycloalkyloxy optionally substituted with one or more R1d;
• each R1d is independently halogen, hydroxy, lower alkyl, lower alkoxy, lower hydroxyalkyl, amino, amido, cyano, or lower haloalkyl;
• each R1e is independently H, lower alkyl, lower alkoxy, —CN, lower haloalkyl, phenyl, heteroaryl, cycloalkyl, or heterocycloalkyl;
• R1f is independently H, lower alkyl, lower haloalkyl, lower alkenyl, phenyl, heteroatyl, cycloalkyl, or heterocycloalkyl;
• R2 is N(R2a)2;
• each R2a is independently H or R2b;
• each R2b is independently lower alkyl, lower alkoxy, phenyl, heteroaryl, cycloalkyl, heterocycloalkyl, or heterocycloalkyl alkylene, optionally substituted with one or more R2c;
• R2c is R2d or R2e;
• each R2d is independently halogen, oxo, or hydroxy;
• each R2e is independently —N(R2g)2, —C(═O)(R2g), —C(═O)O(R2g), —C(═O)N(R2g)2, —N(R2g)C(═O)(R2g), —S(═O)2(R2g), —S(O)2N(R2g)2, lower alkyl, lower alkoxy, lower haloalkyl, phenyl, heteroaryl, heteroaryloxy, cycloalkyl, or heterocycloalkyl, optionally substituted with one or more R2f;
• each R2f is independently H, halogen, lower alkyl, lower alkoxy, or lower haloalkyl;
• each R2g is independently H, lower alkyl, lower alkoxy, lower haloalkyl, or phenyl;
• R3 is —C(═O)R3a,
• R3a is lower alkyl, lower alkoxy, phenyl, or N(R3b)2;
• each R3b is independently H or lower alkyl;
• R4 is —O(R4a);
• R4a is H or R4b;
• R4b is lower alkyl, phenyl, benzyl, lower haloalkyl, cycloalkyl, heterocycloalkyl, heteroaryl, optionally substituted with one or more R4c;
• each R4c is independently halogen, hydroxy, lower alkyl, lower haloalkyl, or lower alkoxy;
• Q1 is phenyl, optionally substituted with one or more Q1a,
• each Q1a is independently Q1b or Q1c,
• each Q1b is independently halogen, hydroxy, —CN, —S(Q1e), —S(O)2(Q1e), or —S(═O)(Q1e);
• each Q1c is independently Q1d or Q1e;
• each Q1d is independently —O(Q1e), —S(═O)2(Q1e), —C(═O)N(Q1e)2, —S(═O)(Q1e), —N(Q1e)S(═O)2(Q1e), —C(═O)(Q1e), —C(═O)O(Q1e), —N(Q1e)C(═O)(Q1e), —N(Q1e)C(═O)O(Q1e), —Si(Q1e)3, or —N(Q1e)C(═O)N(Q1e)2;
• each Q1e is independently H or Q1e′;
• each Q1e′ is independently lower alkenyl, phenyl, lower haloalkyl, lower thioalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkyl alkylene, or heteroaryl, optionally substituted with one or more Q1f;
• each Q1f is independently Q1g or Q1h;
• each Q1g is independently halogen, hydroxy, oxo, —(C(Q1h)2)mS(O)2(Q1h), —(C(Q1h)2)mN(Q1h)(C(Q1h)2)mS(O)2(Q1h), —(C(Q1h)2)mN(Q1h)2, —(C(Q1h)2)mC(═O)(Q1h), or —N(Q1h)C(═O)(Q1h);
• each m is independently 0, 1, or 2;
• each Q1h is independently Q1i or Q1j;
• each Q1i is independently H or hydroxy;
• each Q1j is independently lower alkyl, lower haloalkyl, lower alkoxy, lower thioalkyl, cyano, amino, phenyl, benzyl, cycloalkyl, heterocycloalkyl, or heteroaryl, optionally substituted with one or more Q1k;
• each Q1k is independently halogen, hydroxy, lower alkyl, lower haloalkyl, lower hydroxyalkyl, amino, lower thioalkyl, lower alkoxy, or cyano;
• X is X1 or X2;
• X1 is H, halogen, or hydroxy;
• X2 is lower alkyl, lower alkoxy, lower haloalkyl, phenyl, cycloalkyl, heterocycloalkyl, or heteroaryl, optionally substituted with one or more X2′;
• each X2′ is independently hydroxy, halogen, lower alkyl, lower alkoxy, lower haloalkyl, cycloalkyl, heterocycloalkyl, or heteroaryl;
• or a pharmaceutically acceptable salt thereof.